- UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN RE: ALLERGAN BIOCELL TEXTURED BREAST IMPLANT PRODUCTS LIABILITY LITIGATION MDL No. 2921 (SEE ATTACHED SCHEDULE) CONDITIONAL TRANSFER ORDER (CTO —38) On December 18, 2019, the Panel transferred 4 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 412 F.Supp.3d 1361 (J.P.M.L. 2019). Since that time, 130 additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Brian R. Martinotti. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Martinotti. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of December 18, 2019, and, with the consent of that court, assigned to the Honorable Brian R. Martinotti. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel. Inasmuch as no objection is FOR THE PANEL: pending at this time, the stay is lifted. LL □□ —— Aug 16, 2021 ( OrUNTED STE John W. Nichols MULTIDISTRICT LITIGATION Clerk of the Panel & IN RE: ALLERGAN BIOCELL TEXTURED BREAST IMPLANT PRODUCTS LIABILITY LITIGATION MDL No. 2921 SCHEDULE CTO-38 — TAG-ALONG ACTIONS DIST DIV. C.A.NO. CASE CAPTION NEVADA NV 2 21-01449 Norman v. Allergan, Inc., et al NV 2 21-01451 Base v. Allergan USA, Inc. et al
Document Info
Docket Number: 2:21-cv-01451
Filed Date: 8/16/2021
Precedential Status: Precedential
Modified Date: 6/25/2024